Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Age-related changes in B cell metabolism.

Kurupati RK, Haut LH, Schmader KE, Ertl HC.

Aging (Albany NY). 2019 Jul 8;11(13):4367-4381. doi: 10.18632/aging.102058.

2.

New Rabies Vaccines for Use in Humans.

Ertl HCJ.

Vaccines (Basel). 2019 Jun 20;7(2). pii: E54. doi: 10.3390/vaccines7020054. Review.

3.

Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.

Henry C, Zheng NY, Huang M, Cabanov A, Rojas KT, Kaur K, Andrews SF, Palm AE, Chen YQ, Li Y, Hoskova K, Utset HA, Vieira MC, Wrammert J, Ahmed R, Holden-Wiltse J, Topham DJ, Treanor JJ, Ertl HC, Schmader KE, Cobey S, Krammer F, Hensley SE, Greenberg H, He XS, Wilson PC.

Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6. doi: 10.1016/j.chom.2019.01.002. Epub 2019 Feb 19.

PMID:
30795982
4.

Human immune responses to traditional and novel rabies vaccines.

Ertl HCJ.

Rev Sci Tech. 2018 Aug;37(2):649-656. doi: 10.20506/rst.37.2.2830.

PMID:
30747120
5.

Coaching tumor-infiltrating CD8+ T cells to eat right.

Kurupati R, Ertl HC.

Oncoscience. 2018 Aug 24;5(11-12):276-277. doi: 10.18632/oncoscience.466. eCollection 2018 Nov. No abstract available.

6.

A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis.

Wang C, Dulal P, Zhou X, Xiang Z, Goharriz H, Banyard A, Green N, Brunner L, Ventura R, Collin N, Draper SJ, Hill AVS, Ashfield R, Fooks AR, Ertl HC, Douglas AD.

PLoS Negl Trop Dis. 2018 Oct 29;12(10):e0006870. doi: 10.1371/journal.pntd.0006870. eCollection 2018 Oct.

7.

Immune response to influenza vaccination in the elderly is altered by chronic medication use.

Agarwal D, Schmader KE, Kossenkov AV, Doyle S, Kurupati R, Ertl HCJ.

Immun Ageing. 2018 Aug 31;15:19. doi: 10.1186/s12979-018-0124-9. eCollection 2018.

8.

New human rabies vaccines in the pipeline.

Fooks AR, Banyard AC, Ertl HCJ.

Vaccine. 2019 Oct 3;37 Suppl 1:A140-A145. doi: 10.1016/j.vaccine.2018.08.039. Epub 2018 Aug 25.

9.

Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma.

Kurupati RK, Zhou X, Xiang Z, Keller LH, Ertl HCJ.

Cancer Immunol Immunother. 2018 Oct;67(10):1533-1544. doi: 10.1007/s00262-018-2201-5. Epub 2018 Jul 26.

PMID:
30051333
10.

Erratum: Rupprecht, C.E., et al. Additional Progress in the Development and Application of a Direct, Rapid Immunohistochemical Test for Rabies Diagnosis. Vet. Sci. 2018, 5, 59.

Rupprecht CE, Xiang Z, Servat A, Franka R, Kirby J, Ertl HCJ.

Vet Sci. 2018 Jul 20;5(3). pii: E68. doi: 10.3390/vetsci5030068. No abstract available.

11.

Additional Progress in the Development and Application of a Direct, Rapid Immunohistochemical Test for Rabies Diagnosis.

Rupprecht CE, Xiang Z, Servat A, Franka R, Kirby J, Ertl HCJ.

Vet Sci. 2018 Jun 20;5(2). pii: E59. doi: 10.3390/vetsci5020059. Erratum in: Vet Sci. 2018 Jul 20;5(3):.

12.

Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors.

Tuyishime S, Haut LH, Kurupati RK, Billingsley JM, Carnathan D, Gangahara S, Styles TM, Xiang Z, Li Y, Zopfs M, Liu Q, Zhou X, Lewis MG, Amara RR, Bosinger S, Silvestri G, Ertl HCJ.

EBioMedicine. 2018 May;31:25-35. doi: 10.1016/j.ebiom.2018.02.025. Epub 2018 Mar 4.

13.

Coaching tumor-infiltrating CD8+ T cells to eat right.

Kurupati R, Ertl HC.

Oncoscience. 2018 Jan 22;5(1-2):1-2. doi: 10.18632/oncoscience.390. eCollection 2018 Jan. No abstract available.

14.

Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013.

Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, Halpin RA, Lin X, Stockwell TB, Das SR, Landon E, Tesic V, Youngster I, Pinsky BA, Wentworth DE, Hensley SE, Grad YH.

Clin Infect Dis. 2018 Jul 18;67(3):327-333. doi: 10.1093/cid/ciy097.

15.

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.

de Camargo TM, de Freitas EO, Gimenez AM, Lima LC, de Almeida Caramico K, Françoso KS, Bruna-Romero O, Andolina C, Nosten F, Rénia L, Ertl HCJ, Nussenzweig RS, Nussenzweig V, Rodrigues MM, Reyes-Sandoval A, Soares IS.

Sci Rep. 2018 Jan 18;8(1):1118. doi: 10.1038/s41598-017-19063-6.

16.

Preclinical models to assess the immunogenicity of AAV vectors.

Ertl HCJ.

Cell Immunol. 2019 Aug;342:103722. doi: 10.1016/j.cellimm.2017.11.006. Epub 2017 Nov 23.

PMID:
29195742
17.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz JD, Ertl HCJ.

Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

18.

The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged.

Kurupati RK, Kossenkoff A, Kannan S, Haut LH, Doyle S, Yin X, Schmader KE, Liu Q, Showe L, Ertl HCJ.

Vaccine. 2017 Jun 27;35(30):3700-3708. doi: 10.1016/j.vaccine.2017.05.074. Epub 2017 Jun 2.

PMID:
28583307
19.

Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in vivo.

Afkhami S, LeClair DA, Haddadi S, Lai R, Toniolo SP, Ertl HC, Cranston ED, Thompson MR, Xing Z.

Vaccine. 2017 May 19;35(22):2916-2924. doi: 10.1016/j.vaccine.2017.04.026. Epub 2017 Apr 21.

PMID:
28438408
20.
21.
22.

Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Emmer KL, Wieczorek L, Tuyishime S, Molnar S, Polonis VR, Ertl HC.

AIDS. 2016 Oct 23;30(16):2405-2414.

23.

A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Haut LH, Gill AL, Kurupati RK, Bian A, Li Y, Giles-Davis W, Xiang Z, Zhou XY, Ertl HC.

Hum Gene Ther Methods. 2016 Oct;27(5):187-196. doi: 10.1089/hgtb.2016.044. Epub 2016 Sep 7. Erratum in: Hum Gene Ther Methods. 2017 Feb;28(1):60.

24.

Viral vectors as vaccine carriers.

Ertl HC.

Curr Opin Virol. 2016 Dec;21:1-8. doi: 10.1016/j.coviro.2016.06.001. Epub 2016 Jun 18. Review.

PMID:
27327517
25.

Aging: T cell metabolism within tumors.

Zhang Y, Ertl HC.

Aging (Albany NY). 2016 Jun;8(6):1163-4. doi: 10.18632/aging.100979. No abstract available.

26.

Vaccine Design: Replication-Defective Adenovirus Vectors.

Zhou X, Xiang Z, Ertl HC.

Methods Mol Biol. 2016;1404:329-49. doi: 10.1007/978-1-4939-3389-1_23.

PMID:
27076309
27.

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.

Vercauteren K, Hoffman BE, Zolotukhin I, Keeler GD, Xiao JW, Basner-Tschakarjan E, High KA, Ertl HC, Rice CM, Srivastava A, de Jong YP, Herzog RW.

Mol Ther. 2016 Jun;24(6):1042-1049. doi: 10.1038/mt.2016.61. Epub 2016 Mar 29.

28.

Age-related changes in the transcriptome of antibody-secreting cells.

Kannan S, Dawany N, Kurupati R, Showe LC, Ertl HC.

Oncotarget. 2016 Mar 22;7(12):13340-53. doi: 10.18632/oncotarget.7958.

29.

Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.

Zhang Y, Ertl HC.

Oncotarget. 2016 Apr 26;7(17):23282-99. doi: 10.18632/oncotarget.7818.

30.

Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression.

Zhang Y, Ertl HC.

Front Immunol. 2016 Feb 10;7:32. doi: 10.3389/fimmu.2016.00032. eCollection 2016. Review.

31.

A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged.

Kannan S, Kossenkov A, Kurupati RK, Xiang JZ, Doyle SA, Schmader KE, Schowe L, Ertl HC.

Aging (Albany NY). 2015 Dec;7(12):1077-85.

32.

BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.

Kannan S, Kurupati RK, Doyle SA, Freeman GJ, Schmader KE, Ertl HC.

Oncotarget. 2015 Aug 14;6(23):19445-55.

33.

Gene therapy and gene transfer approaches to prevent or treat chronic virus infections.

Berkout B, Ertl HC, Weinberg MS.

Adv Exp Med Biol. 2015;848:v-vii. No abstract available.

PMID:
26034787
34.

Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation.

Song Y, Wang X, Zhang H, Tang X, Li M, Yao J, Jin X, Ertl HC, Zhou D.

J Virol. 2015 Aug;89(15):7841-51. doi: 10.1128/JVI.00976-15. Epub 2015 May 20.

35.

Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Jeyanathan M, Thanthrige-Don N, Afkhami S, Lai R, Damjanovic D, Zganiacz A, Feng X, Yao XD, Rosenthal KL, Medina MF, Gauldie J, Ertl HC, Xing Z.

Mucosal Immunol. 2015 Nov;8(6):1373-87. doi: 10.1038/mi.2015.29. Epub 2015 Apr 15.

PMID:
25872483
36.

Adenovirus-mediated artificial MicroRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge.

Zhang H, Tang X, Zhu C, Song Y, Yin J, Xu J, Ertl HC, Zhou D.

Gene Ther. 2015 Aug;22(8):653-62. doi: 10.1038/gt.2015.31. Epub 2015 Apr 23.

PMID:
25835311
37.

Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer.

Rogers GL, Suzuki M, Zolotukhin I, Markusic DM, Morel LM, Lee B, Ertl HC, Herzog RW.

J Innate Immun. 2015;7(3):302-14. doi: 10.1159/000369273. Epub 2015 Jan 20.

38.

Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.

Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, Yan J, Morrow MP, Sardesai NY, Weiner DB, Ertl HC, Silvestri G.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):518-23. doi: 10.1073/pnas.1407466112. Epub 2014 Dec 30.

39.

Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models.

Chi Y, Wang X, Yang Y, Zhang C, Ertl HC, Zhou D.

Mol Ther Nucleic Acids. 2014 Nov 4;3:e208. doi: 10.1038/mtna.2014.59.

40.

The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.

Small JC, Haut LH, Bian A, Ertl HC.

J Leukoc Biol. 2014 Nov;96(5):821-31. doi: 10.1189/jlb.1A0813-451RR. Epub 2014 Jul 31.

41.

The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.

Zhang Y, Ertl HC.

J Immunol. 2014 Aug 15;193(4):1836-46. doi: 10.4049/jimmunol.1302029. Epub 2014 Jul 14.

42.

Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid.

Tuyishime S, Haut LH, Zhu C, Ertl HC.

Vaccine. 2014 Jun 5;32(27):3386-92. doi: 10.1016/j.vaccine.2014.04.028. Epub 2014 Apr 26.

43.

Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Leskowitz R, Fogg MH, Zhou XY, Kaur A, Silveira EL, Villinger F, Lieberman PM, Wang F, Ertl HC.

J Virol. 2014 May;88(9):4721-35. doi: 10.1128/JVI.03744-13. Epub 2014 Feb 12.

44.

Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE.

Virology. 2014 Feb;450-451:243-9. doi: 10.1016/j.virol.2013.12.029. Epub 2014 Jan 9.

45.

Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.

Teixeira LH, Tararam CA, Lasaro MO, Camacho AG, Ersching J, Leal MT, Herrera S, Bruna-Romero O, Soares IS, Nussenzweig RS, Ertl HC, Nussenzweig V, Rodrigues MM.

Infect Immun. 2014 Feb;82(2):793-807. doi: 10.1128/IAI.01410-13. Epub 2013 Dec 9.

46.

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.

Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW.

J Transl Med. 2014 Jan 25;12:25. doi: 10.1186/1479-5876-12-25.

47.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

48.

Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes.

Small JC, Kurupati RK, Zhou X, Bian A, Chi E, Li Y, Xiang Z, Ertl HC.

Hum Gene Ther. 2014 Apr;25(4):328-38. doi: 10.1089/hum.2013.216. Epub 2014 Mar 25.

49.

Influenza virus specific CD8⁺ T cells exacerbate infection following high dose influenza challenge of aged mice.

Parzych EM, DiMenna LJ, Latimer BP, Small JC, Kannan S, Manson B, Lasaro MO, Wherry EJ, Ertl HC.

Biomed Res Int. 2013;2013:876314. doi: 10.1155/2013/876314. Epub 2013 Sep 26.

50.

Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans.

Dolfi DV, Mansfield KD, Kurupati RK, Kannan S, Doyle SA, Ertl HC, Schmader KE, Wherry EJ.

PLoS One. 2013 Oct 14;8(10):e77164. doi: 10.1371/journal.pone.0077164. eCollection 2013.

Supplemental Content

Support Center